

An Elsevier Indexed Journal

ISSN-2230-7346



# Journal of Global Trends in Pharmaceutical Sciences

Research Article

# EFFECT OF ETHANOLIC EXTRACT OF STEM BARK OF SCHREBERA SWIET-ENIOIDES AGAINST STREPTOZOTOCIN INDUCED DIABETES IN RATS

# Gudimallam Dileep Kumar\*, R.Radha, B.Pushpa Kumari, D.Ranganayakulu

Department of Pharmaceutical chemistry, Sri Padmavathi School of Pharmacy, Tiruchanoor, Tirupati, Andhra Pradesh, Pincode-517503

# ARTICLE INFO ABSTRACT

Key words:

Diabetes mellitus, Streptozotocin, Schrebera swietenioides, Na<sup>+</sup>/K<sup>+</sup> ATPases, Oxidative stress.



Diabetes mellitus (DM) is a group of metabolic diseases characterized by hyperglycemia. Symptoms include polydypsia, polyphagia, blurred vision, polyurea, weight loss and vascular complications with high rate of mortality. Despite the availability of many synthetic antidiabetic drugs, its treatment has many serious complications. So still remains a challenge for developing a potent antidiabetic drug. The aim of the present study was to evaluate the effect of ethanolic extract of stem bark of schrebera swietenioides (EESBSS) against streptozotocin (STZ) (60mg/kg, i.p) induced diabetes in rats. Oral glucose tolerance test (OGTT) was carried out to confirm hypoglycemic activity of EESBSS. Albino male Wistar rats (180-200g) were randomly selected after inducing hyperglycemia (blood glucose >250mg/dl) and divided into Normal, Control, Standard (5mg/kg, p.o. Glibenclamide), T<sub>1</sub> (250mg/kg, p.o. EESBSS), T<sub>2</sub> (500mg/kg, p.o. EESBSS). Animals were sacrificed, diffused pancreas were isolated to determine Na<sup>+</sup>/K<sup>+</sup> ATPases activity and oxidative stress. EESBSS showed significant reduction in blood glucose and improvement in Na<sup>+</sup>/K<sup>+</sup> ATPases activity compared to control group. The activity of antioxidant enzymes were significantly enhanced while LPO levels were significantly reduced. Significant increase in the function of Na<sup>+</sup>/K<sup>+</sup> ATPases shows that the plant extract may have offered protection to the cells of pancreas. The results revealed that EESBSS possess significant antidiabetic activity. It also improved the pancreas membrane integrity by significant increase in Na<sup>+</sup>/K<sup>+</sup> ATPases activity and antioxidant effect. Further studies are necessary to elucidate the mechanism of action of the plant at cellular and molecular level.

#### \*Address for correspondence

## **Gudimallam Dileep Kumar\***

Department of Pharmaceutical chemistry, Sri Padmavathi School of Pharmacy, Tiruchanoor, Tirupati, Andhra Pradesh -517503 E-mail: dileepg92@gmail.com

#### INTRODUCTION

For centuries, medicinal herbs have been used to treat all types of health maladies. In fact, modern medicine is essentially based on herbal medicine. Even today in the times of advanced technology and medical science still depend on plants for their healing. These medicinal plants consider as a rich source of ingredients which can be used in drug develop-

ment and synthesis. Medicinal plants exhibit phytotherapeutic effects caused by biologically active compounds specific secondary metabolites. Schrebera Swietenioides belonging to the family Oleaceae, claimed to be useful as antidiabetic, appetizing, digestive, constipating, anthelmintic, purgative and stomachic.[1,2] It also used in flatulence, skin diseases, leprosy, diarrhoea, anaemia and rectal disease.[3,4] Many of the indigenous plants are still left unexplored for their claimed uses one of such plant is Schrebera swietenioides stem bark claimed to be useful as antidiabetic but still the scientific reports are not available for supporting the claim. Hence the present study was undertaken to evaluate the antidiabetic activity for the stem bark of schrebera swietenioides.



#### Schrebera swietenioides stem bark

Diabetes mellitus is a syndrome characterized by chronic hyperglycemia and relative insulin deficiency, resistance or both.[5] Till date, it has already affected more than 120 million people worldwide, according to an estimate, 220 million people will be affected by the year 2020.[6] Hence it is imperative to intervene and look for new drugs to manage this metabolic disorder. Use of herbal remedies is gaining higher importance because of synthetic drugs have drawbacks and limitations. The available ethanobotanical information accounts for about 800 plants that may possess anti-diabetic potential.[7] The herbal drugs with antidiabetic activity are extensively formulated commercially because of easy availability, affordability and less side effects as compared to the synthetic antidiabetic drugs. Hence always there is a scope for the development of alternative medicine for diabetes among which herbal medicine is first and foremost.[8] Thus the present study was undertaken to evaluate the effect of ethanolic extract of stem bark of schrebera swieten*ioides* (EESBSS) against streptozotosin (STZ) induced diabetes in rats.

#### MATERIALS AND METHODS

#### ANIMALS

Male albino rats of Wistar strain weighing 150-200g body weight were obtained from Raghavendra enterprises, Bangalore. Animals were maintained under standard laboratory conditions with normal dark and light cycles and room temperature.

#### **CHEMICALS**

Streptozotocin was procured from HI-media chem. Limited, Mumbai. Standard drug Glibenclamide was procured from Aurobindo labs Ltd.; Diagnostic kits used in this study were procured from Span diagnostics Ltd., India. All the other chemicals used were of analytical grade.

## **INSTRUMENTS**

Electronic balance (Shimdazu, model no: DS-852 j), Auto analyzer (Mispa Excell), Cooling Centrifuge (Remi, model no: C-24BL).

## **COLLECTION OF PLANT MATERIAL**

The plant material for the present study was collected from surrounding of Tirumala hills and authenticated by Dr. B. Sitaram, Professor, S.V. Ayurvedic medical college, Tirupati. The *Schrebera swietenioides* was powdered in Wiley mill and extracted with ethanol.

#### PREPARATION OF EXTRACT

The collected plant material was washed thoroughly in water, chopped, shade dried at room temperature, reduced to a coarse powder in a mechanical grinder and passed through a 40# sieve for desired particle size. In powder, obtained 1 kg of stem bark of *Schrebera Swietenioides* was subjected for hot extraction by using 95% ethanol as a solvent. The extract was concentrated in vaccum. The percentage yield of ethanol extract of *Schrebera swietenioides* was 16 % (w/w).

The obtained extract was stored in a refrigerator at 2-8 °C until usage.

## PRELIMINARY PHYTOCHEMICAL IN-VESTIGATION

Phytochemical investigation of EESBSS reveals the presence of alkaloids, glycosides (cardiac, anthraquinones), tannins, steroids and triterpenoids, flavanoids in the *Schrebera Swietenioides* plant.

## **EXPERIMENTAL METHODS**

An Institutional Animal Ethics Committee of Sri Padmavathi School of Pharmacy Tiruchanoor, Tirupati (SPSP/CPCSEA/IAEC-1016/a/2014/020), approved the experimental protocol.

# Acute toxicity studies

The acute toxicity studies were performed according to the OECD 423 guidelines. The plant extract was administered orally at the four doses of 5, 50, 300 and 2000mg/kg body weight and they were subsequently observed closely for the first 4h for any untoward symptoms such as tremors, convulsions, salivation, diarrhea and lethargy followed by observation for a further 14 days. At the end of the experimental period, the animals were observed for any changes in behavioural pattern and mortality.[9]

## **Experimental design**

Animals were divided into five groups, each group consisting of six (n=6) rats of which each group receiving respective treatments per orally for 14 days as shown in the Table-1.

# **Oral glucose tolerance test (OGTT)**

Hypoglycemic activity was studied in glucose overloaded hyperglycemic rats. The animals were divided into four groups (n=6). Group-I served as normal, group-II as control received vehicle; the remaining three groups were treated orally with 200mg/kg, 400mg/kg and 800mg/kg of EESBSS. Zero hour blood sugar level was determined from overnight fasted animals. After 30 min of the drug treatment (*p.o.*), the animals were fed with glucose (4kg/kg) and blood glucose was determined

after 0.5, 1, 2, and 3 hours of the glucose load. Blood glucose concentration was estimated by the glucose oxidase enzymatic method using glucose kits.[10]

# Streptozotocin induced diabetes models in rats [11]

In the present study, diabetes was induced by single intra peritoneal injection of streptozotocin (60mg/kg).[12] The streptozotocin was freshly prepared by dissolving 60mg in 1ml citrate buffer (pH 7.4). The animals were allowed to drink 5% glucose solution overnight to overcome the drug-induced hypoglycemia. 72 hrs after injection of streptozotocin, fasting plasma blood glucose was estimated. Animals with plasma glucose of >250g/dl [13] were randomly divided into groups II-IV, (n=6). Group-II includes control and remaining groups were treated with ethanolic extract of *Schrebera swietenioides* at different doses for 14 days.

# Estimation of blood glucose levels

Blood glucose was estimated by using Glucose oxidase (GOD) and Peroxidase (POD) method.[14]

## Estimation of Na<sup>+</sup>/K<sup>+</sup> ATPases

Na<sup>+</sup>/K<sup>+</sup> ATPases was assayed by taking 250ml of Tris Hcl (184mM; pH 7.5) buffer followed by the addition of 50 ml of 600mM Nacl, 50ml of 50mM Kcl, along with 50ml of 1Mm Na-EDTA and 50ml of 80Mm ATP. The reaction mixture was pre-incubated at 37°C for 10 min. then 25ml of 10% homogenate was added to test alone and further incubated at 37°C for I h. the reaction was immediately arrested by the addition of 10% trichloro acetic acid (TCA). Control samples were carried out under the same conditions with the addition of 0.1mM ouabain. The precipitate was removed by centrifugation at 3500 rpm for 10min. the supernatant (0.5ml) was used for the estimation of inorganic phosphorous. The specific activity of the enzyme corresponds to the difference between the total ATPases activity and the activity measure in the presence of 1mM ouabain (ouabain-resistant activity).

Table-1: Treatment schedule for evaluation of anti diabetic activity

| Group No | Treatment   | Purpose  |  |
|----------|---|--|--|
| I        | No treatment  | To serve as normal   |  |
| II       | Streptozotocin (60mg/kg, <i>i.p</i> ) + Distilled water                     | To serve as control  |  |
| III      | Streptozotocin (60mg/kg, <i>i.p</i> ) + Glibenclamide (5mg/kg, <i>p.o</i> ) | To serve as standard   |  |
| IV       | Streptozotocin (60mg/kg, <i>i.p</i> ) + EESBSS (250mg/kg, <i>p.o</i> )      | To study the antidiabetic effect of low dose of <i>S. swietenioides</i>  |  |
| V        | Streptozotocin (60mg/kg, <i>i.p</i> ) + EESBSS (500mg/kg, <i>p.o</i> )      | To study the antidiabetic effect of high dose of <i>S. swietenioides</i> |  |

Table-2: Effect of EESBSS on oral glucose tolerance test

| Group | Treatment              | Serum glucose (mg/dl) (Mean ± SEM) |          |         |         |         |
|-------|------------------------|------------------------------------|----------|---------|---------|---------|
|       |                        | 0 min                              | 30 min   | 60 min  | 90 min  | 120 min |
| I     | Normal                 | 75.53 ±                            | 110.0±   | 120.9 ± | 101.5 ± | 93.3 ±  |
|       |                        | 7.14                               | 6.47     | 9.94    | 6.64    | 12.04   |
| II    | Glibenclamide (5mg/kg) | 58.14 ±                            | 85.53 ±  | 75.35 ± | 69.64 ± | 62.58 ± |
|       |                        | 6.87a                              | 7.05a    | 6.55a   | 6.38a   | 5.47a   |
| III   | EESBSS (250mg/kg)      | 85.89 ±                            | 120.84 ± | 95.97 ± | 87.48 ± | 77.43 ± |
|       |                        | 6.39b                              | 4.84b    | 8.05b   | 7.79b   | 8.03b   |
| IV    | EESBSS (500mg/kg)      | 80.09 ±                            | 130.0 ±  | 91.01 ± | 82.11 ± | 71.6 ±  |
|       |                        | 6.34b                              | 1.02b    | 5.18b   | 7.33b   | 10.24b  |

a = p < 0.05, when compared to normal. b = p < 0.05, when compared to normal.

Table-3: Effect of EESBSS on blood glucose levels

| Group | Treatment              | 0 <sup>th</sup> day | 7 <sup>th</sup> day    | 14 <sup>th</sup> day   |
|-------|------------------------|---------------------|------------------------|------------------------|
| I     | Normal                 | $82.12 \pm 0.940$   | $88.52 \pm 4.11$       | $86.46 \pm 4.89$       |
| II    | Control                | $230.41 \pm 15.53$  | $239.54 \pm 13.34^{a}$ | $242.14 \pm 15.31^{a}$ |
| III   | Glibenclamide (5mg/kg) | $218.09 \pm 15.23$  | $100.38 \pm 8.86^{b}$  | $89.51 \pm 5.53^{b}$   |
| IV    | EESBSS (250mg/kg)      | $201 \pm 14.42$     | $120 \pm 9.93^{b}$     | $99 \pm 4.66^{b}$      |
| V     | EESBSS (500mg/kg)      | $190 \pm 13.83$     | $113 \pm 10.15^{b}$    | $91 \pm 5.12^{b}$      |

a = p < 0.05, when compare to normal. b = p < 0.05, when compare to control.

Table-4: Effect of EESBSS on Na<sup>+</sup>/K<sup>+</sup> ATPases activty in diabetic rats

| Group | Treatment              | Na <sup>+</sup> /K <sup>+</sup> ATPases activity (μmol Pi/me:/h) |
|-------|------------------------|--|
| I     | Normal                 | $2.000 \pm 0.051$  |
| II    | Control                | $0.619 \pm 0.113^{a}$  |
| III   | Glibenclamide (5mg/kg) | $1.013 \pm 0.002^{b}$  |
| IV    | EESBSS (250mg/kg)      | $1.463 \pm 0.139^{b}$  |
| V     | EESBSS (500mg/kg)      | $1.792 \pm 0.197^{b}$  |

a = p < 0.0001, when compared to normal. b = p < 0.0001, when compared to control.

| Wormal | Control | Standard | 250 mg/kg | 500 mg/kg | Groups | Standard | S

Figure-1: Effect of EESBSS on SOD levels in STZ induced diabetes model

All values are shown as Mean  $\pm$  SEM and n=6. \* indicates p < 0.05 when compared with normal. \*\*indicates p < 0.05 when compared with control




Figure-2: Effect of EESBSS on CAT levels in STZ induced diabetes model

All values are shown as Mean  $\pm$  SEM and n=6. \* indicates p < 0.05 when compared with normal. \*\*indicates p < 0.05 when compared with control




Figure-3: Effect of EESBSS on reduced GSH in STZ induced diabetes model

All values are shown as Mean  $\pm$  SEM and n=6. \* indicates p < 0.05 when compared with normal. \*\*indicates p < 0.05 when compared with control




Figure-4: Effect of EESBSS on LPO in STZ induced diabetes model

All values are shown as Mean  $\pm$  SEM and n=6. \* indicates p < 0.05 when compared with normal. \*\*indicates p < 0.05 when compared with control

#### **Estimation of oxidative stress**

Lipid peroxidase was estimated and it was calculated on the basis of the molar extinction coefficient of malondialdehyde (MDA) and expressed in terms nanomolar of MDA/mg protein.

# Antioxidant assays

The enzymatic antioxidants such as superoxide dismutase & catalase and non enzymatic antioxidants glutathione were estimated in tissue homogenate.

## Statistical analysis

All the data were expressed as the mean  $\pm$  SEM. Statistical difference between means were determined by one way analysis of variance (ANOVA) followed by Dunnet t-test.

## **RESULTS**

From the acute toxicity studies, the results had shown that ethanolic extract of stem bark of *Schrebera swietenioides* has no toxic effects found at the maximum tested dose level of 2000mg/kg.

## **DISCUSSION**

Diabetes mellitus is a debilitating and often life threatening disorder with increasing incidence throughout the world.[15,16]

Hence it was quite interesting to evaluate the potential therapeutic effectiveness of ethanolic extract of Schrebera swietenioides against STZ induced diabetes in rats. Streptozotocin induced diabetes mellitus causes the destruction of pancreatic beta cells of the islets of Langerhans which leads to reduced insulin release. An insufficient release of insulin causes high blood glucose, namely hyperglycemia, which results in oxidative damage by generation of reactive oxygen species (ROS) and the development of diabetic complications.[17,18] Antioxidants have been shown to reduce the risk of diabetes onset, improve glucose disposal and improve some of the associated complications.[19] Plants provide a rich source of antioxidants, which include tocopherols, vitamin-C, phenolic compounds, carotenoids, flavanoids, terpenoids, anthraquinones, steroids, strychnine and eugenol alkaloids.[20,21,22] Na<sup>+</sup> K<sup>+</sup> ATPases are pumps present in the cell membrane of the cells which help in maintenance of cell membrane integrity.[23] In the present study Na<sup>+</sup>K<sup>+</sup> ATPases was significantly increased in the groups treated with test sample showing that the cell membrane integrity of pancreas was retained. This may be helpful for maintenance of the structure of Bcells of pancreas and thereby increasing insulin production.

#### **CONCLUSION**

The results of the present study revealed that ethanolic extract of stem bark of *Schrebera swietenioides* possess significant antidiabetic activity against streptozotocin induced diabetes in rats. Further studies are necessary to explore in detail the mechanism of action of EESBSS at both the cellular and molecular levels.

#### **ACKNOWLEDGEMENT**

The authors are thankful to Principal and management of Sri Padmavathi School of Pharmacy for providing the facilities to carry out this work.

#### REFERENCES

- 1. Orient Longman; Indian Medicinal Plants. First edition, Vol. V, Arya Vaidyasala, Kottakal, 1997: 88-91.
- Kritikar, K.R, Basu, B.D; Indian Medicinal Plants. Vol. II, International Book Publisher, Dehradun, 1993: 1531-1532.
- 3. R.N. Chopra, S.L. Nayar, I.C. Chopra; Glossary of Indian Medicinal Plants. First edition, National Institute of Science Communication (CSIR), New Delhi, 1999: 223.
- 4. K. Madhava chetty, K. Shivaji, K. Tulasi rao; Flowering plants of Chittoor district, A.P, India. Second edition, Students offset printers, Tirupati, 2008: 194.
- 5. Shoback; Chapter 17. Greenspan's basic & clinical endocrinology, Ninth edition, David G. Gardner, Dolores, McGraw-Hill Medical, New York, 2011. ISBN 0-07-162243-8.
- 6. Kumar. P., Clark. M; Clinical Medicine, Diabetes Mellitus and other disorders of metabolism. Vol. II, WB Sunders, London, 2001, 1069-71
- 7. Grover. J.K., Yadav. S., Vats. V; Medicinal plants of India with antidiabet-

- ic potential. J. Ethnopharmacol., 2002; 81–100.
- 8. Satoskar. R.S., Bhandarkar. S.D., Ainapure. S.S; Pharmacology and Pharmacotheraputics, Popular Prakashan, Mumbai, 1999: 874.
- Umamaheshwari, M., K. Ashok kumar, R. Rathi devi, A.T. Sivashanmugam, V. Subhadra devi, T.K. Ravi; Anti-ulcer and in-vitro antioxidant activities of *Jasminum grnadifolium*. Journal of Ethnopharmacology, 2007; 110: 464-470.
- 10. Shirwaikar, A., Rajendran, K., Barik, R; Effect of aqueous bark extract of *Garuga pinnata* in Streptozotocin-Nicotinamide induced type-II Diabetes mellitus. Journal of Ethnopharmacology, 2006; 107: 285-290.
- 11. Rakieten, N., Rakieten, M.L., Nadkarni, M.V; Studies on the diabetogenic action of Streptozotocin. Cancer chemother Rep, 1963; 29: 91-102. [NSC-37917]
- 12. Jagadish Singh, Evaluation of antidiabetic potential of *Ougeinia oojeinensis* leaves in Streptozotocin induced diabetic rats. Pharmacology online, 2011; 2: 1046-1052.
- 13. Rajalakshmi, M., J. Eliza, Cecilia Edel Priya, Nirmala, A., P. Diasy; Antidiabetic properties of *Tinospora cordifolia* stem extracts on Streptozotocin induced diabetic rats. African Journal of Pharmacy and Pharmacology, 2009; 3(5): 171-180.
- Kaplan. L.A; Carbohydrates and metabolite. In: Clinical Chemistry: Theory, Analysis and Co-Relation. Kaplan, L.A, Peace. A.J., C.V. Mosby, Toronto, Canada, 1984.
- 15. Subramonium. A., Babu. V; Standardised Phytomedicines for Diabetes. In: Role of Biotechnology in Medicinal and Aromatic Plants, Irfan Ali Khan and Atiya Khanum Eds., India, 2005: 180-205.

- Koteeswara Rao. N., Srinivas. N; Anti-diabetic and Renoprotective effects of the chloroform extracts of *Terminalia chebula* Retz. Seeds in streptozotocin induced diabetic rats. Compand Alt. Med., 2006; 6-17.
- 17. Mohammad, A.K., A. Bierhaus, S. Sciekofer, H. Tritschler, H. Ziegler and P.P. Nawroth; The role of oxidative stress and NF (B) activation in late diabetic complications. Biofactors, 1999; 10: 175-179. [PMID: 10609877].
- 18. Sabu. M.C., Kuttan, R; Anti-diabetic activity of medicinal plants and its relationship with their antioxidant property. Journal of Ethnopharmacology, 2002; 81: 155-160.
- Letitia M. McCune, Timothy Johns; Antioxidant activity related to plant part, life form and growing condition in some diabetes remedies. Journal of Ethnopharmacology, 2007; 112: 461-469.
- 20. Rashmi, Dayal. R., Subramaniam. V; Indian drugs, 2006; 44(2): 128-131.
- 21. Yamini B Tripathi, Savita Chaurasia, Ekta Tripathi, Anil Upadhey., G.P. Dubey.; *Bacopa monniera* Linn. As an antioxidant: mechanism of action. Indian Journal of Experimental Biology, 1996; 34: 523-526.
- 22. Virendra. S., J.R. Patel, G. Kalpesh, L.K. Tyagi and M.L. Kori; In-vitro Antioxidant Activity and Phytochemical analysis of stem bark of *Balanities roxburghii* Planch. Advances in biological Research, 2009; 3(5-6): 242-246.
- 23. Sovoboda. P., Mossinger. B.; Catecholamines and brain microsomal Na+-K+ ATPase protection against lipoperoxidative damage. Biochem. Pharmacol., 1981; 30: 427-432.